Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT THE SUCCESSFUL COMPLETION OF FIRST BATCH OF IMPLANTATION IN THE FDA IDE PIVOTAL TRIAL FOR LUX-VALVE PLUS

This announcement is made by Jenscare Scientific Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and product development of the Group.

The Board (the "**Board**") of Directors (the "**Director(s)**") of the Company is pleased to announce that LuX-Valve Plus, the Company's proprietary transvenous tricuspid valve replacement system, has recently completed successful implantation of the first batch of enrolled subjects in the pivotal registration clinical trial (the "**Pivotal Trial**") approved by the U.S. Food and Drug Administration ("**FDA**"), representing a breakthrough advancement in its FDA clinical trial and registration progress. Following the receipt of EU MDR CE certification for the product, this achievement marks another vital milestone attained under the Group's globalization strategy.

The Pivotal Trial for the LuX-Valve Plus transvenous tricuspid valve replacement system is a prospective, global multi-center clinical study, with participating sites across the United States, Canada and multiple European countries. It adopts a head-to-head randomized design comparing with the EVOQUE system of Edwards Lifesciences, primarily to evaluate the safety and efficacy of LuX-Valve Plus for patients suffering from severe tricuspid regurgitation.

Benefiting from LuX-Valve Plus's distinctive design advantages and outstanding clinical performance, the Pivotal Trial has been supported and advanced by numerous participating sites worldwide. We will continue to expedite the progress of the Pivotal Trial.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately market and/or commercialize LuX-Valve Plus successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and Chief Executive Officer

Hong Kong, 16 July 2026

As at the date of this announcement, the executive Director is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.